Cite this: *Med. Chem. Commun.*,
2016, 7, 1450

DOI: 10.1039/c6md90031c

www.rsc.org/medchemcomm

Correction: Sustained anti-BCR–ABL activity with pH responsive imatinib mesylate loaded PCL nanoparticles in CML cells

Barbara Cortese,^{ab} Stefania D'Amone,^a Giuseppe Gigli^{acd} and Ilaria Elena Palamà^{*a}

Correction for 'Sustained anti-BCR–ABL activity with pH responsive imatinib mesylate loaded PCL nanoparticles in CML cells' by Barbara Cortese *et al.*, *Med. Chem. Commun.*, 2015, 6, 212–221.

The authors regret their oversight in not referencing their closely related work, previously published in *Biomaterials Science*, in this *MedChemComm* paper. For the benefit of readers the reference is provided below.*

This *MedChemComm* paper presents a comprehensive study of the synthesis of the reported PCL nanoparticles, pH release of the loaded drug, the colocalization of the nanoparticles in cells, and *in vitro* evidence that the drug release was active against a specific molecular target, the oncoprotein BCR–ABL.

The *Biomaterials Science* paper reports the combination of these PCL nanoparticles with polyelectrolyte nanocomplexes for the dual delivery of two drugs, imatinib mesylate and doxorubicin.

*I. E. Palamà, B. Cortese, S. D'Amone, V. Arcadio and G. Gigli, *Biomater. Sci.*, 2015, 3, 361–372.

^a Institute Nanoscience CNR (NNL, CNR-NANO), via Arnesano, Lecce, Italy. E-mail: ilariaelena.palama@nano.cnr.it

^b Department of Physics, University Sapienza, P. le A. Moro 5, Rome, Italy

^c Dept. Matematica e Fisica 'Ennio De Giorgi', University of Salento, via Monteroni, Lecce, Italy

^d Italian Institute of Technology (IIT) – Center for Biomolecular Nanotechnologies, via Barsanti, Arnesano, Italy